ABUS Quote, Financials, Valuation and Earnings

FibroGen has a net margin of -1472.52% compared to Arbutus Biopharma's net margin of -36.87%. Arbutus Biopharma's return on equity of -67.36% beat FibroGen's return on equity of --.

Arbutus Biopharma has a consensus price target of --, signalling upside risk potential of 62.39%. On the other hand FibroGen has an analysts' consensus of $10.00 which suggests that it could grow by 2400%. Given that FibroGen has higher upside potential than Arbutus Biopharma, analysts believe FibroGen is more attractive than Arbutus Biopharma.

Arbutus Biopharma has a beta of 1.842, which suggesting that the stock is 84.177% more volatile than S&P 500. In comparison FibroGen has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.658%.

Arbutus Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FibroGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arbutus Biopharma pays -- of its earnings as a dividend. FibroGen pays out -- of its earnings as a dividend.

Arbutus Biopharma quarterly revenues are $1.3M, which are smaller than FibroGen quarterly revenues of $46.3M. Arbutus Biopharma's net income of -$19.7M is lower than FibroGen's net income of -$17.1M. Notably, Arbutus Biopharma's price-to-earnings ratio is -- while FibroGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma is 85.85x versus 0.22x for FibroGen. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of -1472.52% compared to Arbutus Biopharma's net margin of -4.76%. Arbutus Biopharma's return on equity of -67.36% beat Amicus Therapeutics's return on equity of -71.17%.

Arbutus Biopharma has a consensus price target of --, signalling upside risk potential of 62.39%. On the other hand Amicus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 76.87%. Given that Amicus Therapeutics has higher upside potential than Arbutus Biopharma, analysts believe Amicus Therapeutics is more attractive than Arbutus Biopharma.

Arbutus Biopharma has a beta of 1.842, which suggesting that the stock is 84.177% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.114%.

Arbutus Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arbutus Biopharma pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Arbutus Biopharma quarterly revenues are $1.3M, which are smaller than Amicus Therapeutics quarterly revenues of $141.5M. Arbutus Biopharma's net income of -$19.7M is lower than Amicus Therapeutics's net income of -$6.7M. Notably, Arbutus Biopharma's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma is 85.85x versus 6.02x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

GlycoMimetics has a net margin of -1472.52% compared to Arbutus Biopharma's net margin of --. Arbutus Biopharma's return on equity of -67.36% beat GlycoMimetics's return on equity of --.

Arbutus Biopharma has a consensus price target of --, signalling upside risk potential of 62.39%. On the other hand GlycoMimetics has an analysts' consensus of -- which suggests that it could grow by 327.9%. Given that GlycoMimetics has higher upside potential than Arbutus Biopharma, analysts believe GlycoMimetics is more attractive than Arbutus Biopharma.

Arbutus Biopharma has a beta of 1.842, which suggesting that the stock is 84.177% more volatile than S&P 500. In comparison GlycoMimetics has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.069%.

Arbutus Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlycoMimetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arbutus Biopharma pays -- of its earnings as a dividend. GlycoMimetics pays out -- of its earnings as a dividend.

Arbutus Biopharma quarterly revenues are $1.3M, which are larger than GlycoMimetics quarterly revenues of --. Arbutus Biopharma's net income of -$19.7M is lower than GlycoMimetics's net income of -$9.8M. Notably, Arbutus Biopharma's price-to-earnings ratio is -- while GlycoMimetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma is 85.85x versus -- for GlycoMimetics. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -1472.52% compared to Arbutus Biopharma's net margin of -104.98%. Arbutus Biopharma's return on equity of -67.36% beat Ionis Pharmaceuticals's return on equity of -93.21%.

Arbutus Biopharma has a consensus price target of --, signalling upside risk potential of 62.39%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.36 which suggests that it could grow by 72.16%. Given that Ionis Pharmaceuticals has higher upside potential than Arbutus Biopharma, analysts believe Ionis Pharmaceuticals is more attractive than Arbutus Biopharma.

Arbutus Biopharma has a beta of 1.842, which suggesting that the stock is 84.177% more volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.148%.

Arbutus Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arbutus Biopharma pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Arbutus Biopharma quarterly revenues are $1.3M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $133.8M. Arbutus Biopharma's net income of -$19.7M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Arbutus Biopharma's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma is 85.85x versus 6.48x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.